Preparatory Work to Assess Adherence to Oral Chemotherapy

Wake Forest University (WFU)

Status: Completed

Conditions: Chronic Myeloid Leukemia

Study type: Observational

Funder types: Other

Identifiers

NCT02895542

IRB00039112

REBAWF 99716CD (Other Identifier)

Details and patient eligibility

About

This study to find out more about how patients take their anticancer medications and challenges related to taking cancer medications.

Full description

120 patients with Chronic Myeloid Leukemia (CML) who are currently prescribed an oral anti-cancer agent from up to 6 CCDR NCORP sites to complete a brief interviewer administered survey to assess medication adherence and related factors.

Enrollment: 86 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient is diagnosed with Chronic Myeloid Leukemia (CML) and is receiving care for CML at a participating CCDR NCORP practice,
• Patient had been prescribed one of the following oral anticancer agents for CML for ≥30 days (Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib). Prior use of any of these medications is allowed, as long as they have been on a stable regimen for at least 30 days prior to enrollment.
• Patient is 18 years of age or older

Exclusion criteria

• Patient does not speak English or requires an interpreter for medical visits
• Patient is cognitively impaired, as determined by the referring provider

Trial design

86 participants in 1 patient group

Oral Anti-Cancer Agent

Description:

No intervention